Pages that link to "Q51079603"

The following pages link to Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation (Q51079603):

Displaying 45 items.

• Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications (Q26771106) (← links)
• Impact of Modifiable Cardiovascular Risk Factors on Mortality After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of 100 Studies (Q26774723) (← links)
• Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials (Q26785723) (← links)
• The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data (Q33803660) (← links)
• Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects (Q34186272) (← links)
• The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study (Q35073622) (← links)
• Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). (Q35208684) (← links)
• Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study (Q35677083) (← links)
• Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy (Q35755253) (← links)
• Hypoalbuminaemia, systemic albumin leak and endothelial dysfunction in peritoneal dialysis patients (Q36460761) (← links)
• Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes (Q37022618) (← links)
• Investigating the mechanisms of hyporesponse to antiplatelet approaches (Q37164391) (← links)
• Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions (Q37428365) (← links)
• Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. (Q37451509) (← links)
• P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. (Q37562606) (← links)
• Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients (Q37605071) (← links)
• Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions (Q37678656) (← links)
• Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. (Q37693951) (← links)
• Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. (Q37797795) (← links)
• Clinical Value of Antiplatelet Therapy in Patients with Acute Coronary Syndromes and in Percutaneous Coronary Intervention (Q37841560) (← links)
• The role of antiplatelets in hypertension and diabetes mellitus (Q37861894) (← links)
• The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders (Q37923969) (← links)
• TRITON and Beyond: New Insights into the Profile of Prasugrel (Q37925009) (← links)
• Genetic and non-genetic factors affecting the response to clopidogrel therapy (Q37991382) (← links)
• Platelet function profiles in patients with diabetes mellitus (Q38081078) (← links)
• Dual antiplatelet therapy in patients with diabetes mellitus: special considerations (Q38087381) (← links)
• Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know (Q38132252) (← links)
• Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. (Q38243854) (← links)
• Platelet oxidative stress as a novel target of cardiovascular risk in frail older people. (Q39433616) (← links)
• Determinants to optimize response to clopidogrel in acute coronary syndrome (Q41848961) (← links)
• Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs (Q42795171) (← links)
• Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus (Q43612447) (← links)
• Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. (Q43744458) (← links)
• Platelet Function Profile Post-Clopidogrel Therapy in Patients With Type 2 Diabetes Undergoing Coronary Stent Implantation (Q46358660) (← links)
• Impact of Clopidogrel and Aspirin Treatment on the Expression of Proteins in Platelets from Type-2 Diabetic Patients with Stable Coronary Ischemia (Q46524461) (← links)
• Acute thrombo-embolic elevated ST infarct in a patient with essential thrombocytosis (Q46890739) (← links)
• Inflammation and thrombosis in diabetes (Q52609868) (← links)
• In-hospital, short-term and long-term adverse clinical outcomes observed in patients with type 2 diabetes mellitus vs non-diabetes mellitus following percutaneous coronary intervention: A meta-analysis including 139,774 patients (Q64113067) (← links)
• Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis (Q64282166) (← links)
• Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice. (Q64890735) (← links)
• Challenges in the treatment of patients with essential thrombocythemia and acute coronary syndrome (Q80800569) (← links)
• Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients (Q82806776) (← links)
• Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention (Q83220921) (← links)
• The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: Roles of white blood cell count and body weight (Q84475186) (← links)
• Synthesis and Biological Evaluation of Thio-Derivatives of 2-Hydroxy-1,4-Naphthoquinone (Lawsone) as Novel Antiplatelet Agents (Q98771461) (← links)